High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.
Steven T. Rosen(Unknown), Azra Borogovac(University of Oklahoma Health Sciences Center), Scott Goldsmith(Washington University in St. Louis), Tanya Siddiqi(City Of Hope National Medical Center), Nikhil R. Thiruvengadam(Loma Linda University Medical Center), Geoffrey Shouse(City Of Hope National Medical Center), Annie Xiao(City of Hope), Michael Rosenzweig(Boston University), Firoozeh Sahebi(City Of Hope National Medical Center), Alex F. Herrera(City of Hope), James L. Godfrey(City Of Hope National Medical Center), Nitya Nathwani(City of Hope), Avyakta Kallam(City Of Hope National Medical Center), Diamond Ward(City Of Hope National Medical Center), Murali Janakiram(University of Minnesota), John H. Baird(City Of Hope National Medical Center), Matthew Mei(City of Hope), Kimlin Ashing(City Of Hope National Medical Center), Brian J. Sworder(City Of Hope National Medical Center), Alexey V. Danilov(City of Hope), Myo Htut(City of Hope), Stacy Pak(City Of Hope National Medical Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Tycel Phillips(City of Hope), Nishita Matangi(City Of Hope National Medical Center), Sarah Lee(City Of Hope National Medical Center), Brian Lee(City Of Hope National Medical Center), Diane Lynne Smith(City Of Hope National Medical Center), Amrita Krishnan(City of Hope), M. Ponce(City Of Hope National Medical Center), Ryan Chiechi(City Of Hope National Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k